HomeGenomic Health

Genomic Health

German Health Technology Assessment Body Concludes Only Oncotype DX® Has Sufficient Evidence to Guide Breast Cancer Adjuvant Chemotherapy Decisions Based on Landmark TAILORx Study Results

9/7/18: "With IQWiG's recognition of the unique value the Oncotype DX test provides, we believe we are one step closer to ensuring reimbursed access to tens of thousands of breast cancer patients diagnosed in Germany each year as is the case in other countries around the world including the U.S., Canada, the UK, France, Spain and Switzerland," said Torsten Hoof, Senior Vice President International, Genomic Health.